The codex of science: Honesty, precision, and truth - And its violations

European Heart Journal

Volumn 34, Issue 14, 2013, Pages 1018-1023

  Lüscher, Thomas F ^a  

^a University Hospital of Zurich   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; DATA PROCESSING; DECEPTION; FRAUD; FUNDING; HONESTY; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; MORALITY; PRIORITY JOURNAL; PUBLISHING; REVIEW; SCIENCE; SCIENTIFIC LITERATURE; SCIENTIFIC MISCONDUCT; SCIENTIST;

HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; PLAGIARISM; SCIENCE; SCIENTIFIC MISCONDUCT; TRUST;

EID: 84876245236     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht063     Document Type: Review

References (44)

1. Experiments in Plant Hybridization (1865) by Gregor Mendel, Read at the meetings of February 8th, and March 8th, 1865
2. Versuche über Pflanzen-Hybriden. In: Verhandlungen des naturforschenden Vereines in Brünn. Band IV (Abhandlungen 1865), Brünn 1866, S. 3-47
3. Darwin C. On the Origin of Species. London: John Murray; 1859.
4. Darwin C. The Expression of the Emotions in Man and Animals. London: John Murray; 1872.
5. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. p63-64.
6. Westphal RS. Never at Rest - A Biography of Isaac Newton. Cambridge: Cambridge University Press; 1980.
7. Wittgenstein L. Tractatus Logico-philosophicus. New York: Routledge; 2005. p5.
8. Lüscher TF. Good publishing practice. Eur Heart J 2012;33:557-561.
9. Popper K. Conjectures and Refutations. The Growth of Scientific Knowledge. London: Routledge and Kegan Paul; 1974.
10. Kant I. Critique of Practical Reason. First published in 1788.
11. Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One 2009;4:e5738.
12. Nallamothu B, Lüscher TF. Moving from impact to influence: measurement and the changing role of medical journals. Eur Heart J 2012;33:2892-2996.
13. Marcus A, Oransky I. A retraction epidemic. New York Times 2012;April, p7.
14. Steen RG. Retractions in the scientific literature: is the incidence of research fraud increasing? J Med Ethics 2011;37:249-253.
15. Fang FC, Casadevall A. Retracted science and the retraction index. Infect Immun 2011;79:3855-3859.
16. Notice of Concern. J Am Coll Cardiol 2012;60:2696-2697.
17. Wise J. Extent of Durch psychologist's trial fraud was unprecendented. BMJ 2011; 343:969.
18. O'Riordan M. Erasmus MC fires Poldermans; ESC reviews his work. www. theheart.org/article/1315171.do (27 February 2013).
19. Expression of concern. Circ Res 2012;110:e47.
20. Yoshiki Y. Concerns about the Jikei Heart Study. Lancet 2012;379:e48.
21. Shimokawa H. Urgent announcement from the editor-in-chief concerning atricle retraction. Circ J 2013;77:552b.
22. Lüscher TF. In search of the right word: a statement of the HEART Group on scientific language. Eur Heart J 2013;34:7-9.
23. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. p104-108.
24. Stewart WW, Feder N. The integrity of the scientific literature. Nature 1987;325: 207-214.
25. Braunwald E. On analysing scientific fraud. Nature 1987;325:215-216.
26. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. p110-112.
27. Broad WJ. Imbroglio at Yale: emergence of a fraud. Science 1980;210:38-41 and 10:171-173.
28. Feringa HH, Elhendy A, Bax JJ, Boersma E, de Jonge R, Schouten O, Karagiannis SE, Schinkel AF, Lindemans J, Poldermans D. Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography. Coron Artery Dis 2006:17; 255-259
29. Feringa HH, Bax JJ, Elhendy A, de Jonge R, Lindemans J, Schouten O, van den Meiracker AH, Boersma E, Schinkel AF, Kertai MD, van Sambeek MR, Poldermans D. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol 2006;98:111-115.
30. Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van Poorten F, Bax JJ, Thomson IR, Poldermans D; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249: 921-926.
31. Poldermans D, Schouten O, Benner R, van Urk H, Verhagen HJ, Khan N, Feringa H, Dunkelgrun M, Bax JJ, Boersma E. Fluvastatin XL use is associatedwith improved cardiac outcome after major vascular surgery. Results from a randomized placebo controlled trial: DECREASE III. Circulation 2008;118:S792.
32. Poldermans D, Bax JJ, Schouten O, Neskovic AN, Paelinck B, Rocci G, van Dortmont L, Durazzo AE, van de Ven LL, van Sambeek MR, Kertai MD, Boersma E. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006;48:964-969.
33. Poldermans D, Bax JJ. Dobutamine echocardiography: a diagnostic tool comes of age. Eur Heart J 2003;24;1541-1542.
34. Hoeks SE, Bax JJ, Poldermans D. Should the ACC/AHA guidelines be changed in patients undergoing vascular surgery? Eur Heart J 2005;26:2358-2360.
35. Poldermans D, Bax . Selecting optimal non-invasive cardiac imaging stress test in intermediate-risk patients using cost effectiveness analysis. Eur Heart J 2006;27: 2378-2379.
36. Hoeks SE, Bax JJ, Poldermans D. Indications of prophylactic coronary revascularization in patients undergoing major vascular surgery; the saga continues. Eur Heart J 2007;28:519-521.
37. Schouten O, Bax JJ, Poldermans D. Preoperative cardiac risk assessment in vascular surgery patients; seeing beyond the perioperative period. Eur Heart J 2008;29: 283-284.
38. Flu WJ, Van Kuijk JP, Gorscan J, Poldermans D. Three-dimensional speckle tracking echocardiography: a novel approach in the assessment of left ventricular volume and function? Eur Heart J 2009;30:2304-2307.
39. Van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chronchol M, Vidakowic R, Verhagen HJ, Bax JJ, Poldermans D. Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic disease. Eur Heart J 2010;31:992-999. Wednesday 28 November 2012.
40. Lüscher TF, Gersh B, Brugada J, Landmesser U, Ruschitzka F, Serruys PW on behalf of the new editorial board. The European Heart Journal goes global: the road ahead of the editorial team 2009-2011. Eur Heart J 2009;30:1-5.
41. Head SJ, Kaul S, Bogers AJJC, Kappetein AP. Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Heart J 2012;33;1318-1324.
42. Heinze G, Jüni P. An overview of the objectives of the approaches to propensity analysis. Eur Heart J 2011;32;1704-1708.
43. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Trikalinos TA, Kitsios GD. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 2012;33:1893-1901.
44. Norman C. Reduce fraud in seven easy steps. Science 1984;224;581.